MARKET

REGN

REGN

Regeneron Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

516.62
-0.55
-0.11%
After Hours: 516.62 0 0.00% 16:22 05/14 EDT
OPEN
520.00
PREV CLOSE
517.17
HIGH
521.13
LOW
512.25
VOLUME
783.90K
TURNOVER
--
52 WEEK HIGH
664.64
52 WEEK LOW
441.00
MARKET CAP
55.03B
P/E (TTM)
14.62
1D
5D
1M
3M
1Y
5Y
Polen Focus Growth Fund Disposed its Regeneron Pharmaceuticals (REGN) Position, Here’s Why
Polen Capital, an investment management firm, published its “Polen Focus Growth” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 1.81% was delivered by the fund for the Q1 of 2021, outperforming its Russell 1000 Gro...
Insider Monkey · 3h ago
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first operating loss as a listed company, as a record regulatory fine it was
Benzinga · 15h ago
Legg Mason Asset Management (Japan) Co., Ltd. ...
GuruFocus News · 19h ago
Skba Capital Management Llc Buys VEREIT Inc, International Business Machines Corp, ...
GuruFocus News · 1d ago
Forefront Analytics, LLC Buys Vanguard Short-Term Bond ETF, Invesco Senior Loan ETF, Regeneron ...
GuruFocus News · 1d ago
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Zacks.com · 1d ago
Bitcoin, Bumble, Jack in the Box: What to Watch When the Stock Market Opens Today
Futures point to further declines for U.S. stocks a day after the S&P 500 posted its biggest three-day drop since October.
marketwatch.com · 1d ago
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the stock reversed the earnings-driven gains of the previous session.
Benzinga · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of REGN. Analyze the recent business situations of Regeneron Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average REGN stock price target is 628.36 with a high estimate of 814.00 and a low estimate of 460.00.
EPS
Institutional Holdings
Institutions: 1.24K
Institutional Holdings: 93.92M
% Owned: 88.17%
Shares Outstanding: 106.52M
TypeInstitutionsShares
Increased
360
4.48M
New
138
1.04M
Decreased
276
5.17M
Sold Out
133
1.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.86%
Pharmaceuticals & Medical Research
+1.17%
Key Executives
Chairman/Director
P. Roy Vagelos
President/Chief Executive Officer/Director
Leonard Schleifer
Co-President/Chief Scientific Officer/Director
George Yancopoulos
Chief Financial Officer/Executive Vice President - Finance
Robert Landry
Executive Vice President/General Counsel/Secretary
Joseph LaRosa
Executive Vice President/General Manager
Daniel Van Plew
Executive Vice President
Andrew Murphy
Executive Vice President
Neil Stahl
Senior Vice President
Marion McCourt
Vice President/Controller
Christopher Fenimore
Independent Director
Bonnie Bassler
Independent Director
Michael Brown
Independent Director
N. Anthony Coles
Independent Director
Joseph Goldstein
Independent Director
Christine Poon
Independent Director
Arthur Ryan
Independent Director
George Sing
Independent Director
Marc Tessier-Lavigne
Independent Director
Huda Zoghbi
No Data
About REGN
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.